Related references
Note: Only part of the references are listed.Role of Serotonergic 1A Receptor Dysfunction in Depression Associated with Parkinson's Disease
Benedicte Ballanger et al.
MOVEMENT DISORDERS (2012)
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
Philippe Huot et al.
NEUROBIOLOGY OF AGING (2012)
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
Kristin B. Dupre et al.
EXPERIMENTAL NEUROLOGY (2011)
Role of the primary motor cortex in L-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation
Corinne Y. Ostock et al.
NEUROPHARMACOLOGY (2011)
The serotonergic system in Parkinson's disease
Philippe Huot et al.
PROGRESS IN NEUROBIOLOGY (2011)
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Benedicte Ballanger et al.
ARCHIVES OF NEUROLOGY (2010)
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study
Peter A. Kempster et al.
BRAIN (2010)
Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations
Philippe Huot et al.
MOVEMENT DISORDERS (2010)
Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
Susan H. Fox et al.
MOVEMENT DISORDERS (2009)
The Role of the Dorsal Raphe Nucleus in the Development, Expression, and Treatment of L-dopa-Induced Dyskinesia in Hemiparkinsonian Rats
Karen L. Eskow et al.
SYNAPSE (2009)
Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson's Disease Dementia
Sally I. Sharp et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2008)
L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys
Philippe Huot et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2008)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea
Philippe Huot et al.
BRAIN (2007)
Circuits and circuit disorders of the basal ganglia
Mahlon R. DeLong et al.
ARCHIVES OF NEUROLOGY (2007)
WAY-100635 is a potent dopamine D4 receptor agonist
Benjamin R. Chemel et al.
PSYCHOPHARMACOLOGY (2006)
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Trond Kvernmo et al.
CLINICAL THERAPEUTICS (2006)
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study
DR Williams et al.
LANCET NEUROLOGY (2005)
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors:: affinity, efficacy and potential implications for treatment of schizophrenia
A Newman-Tancredi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2005)
2-[4-(3,4-Dimethylphenyl)piperazin-l-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist
M Nakane et al.
NEUROPHARMACOLOGY (2005)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model
NJ Diederich et al.
MOVEMENT DISORDERS (2005)
Increased D-1 dopamine receptor signaling in levodopa-induced dyskinesia
I Aubert et al.
ANNALS OF NEUROLOGY (2005)
Stages in the development of Parkinson's disease-related pathology
H Braak et al.
CELL AND TISSUE RESEARCH (2004)
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease
D Merims et al.
JOURNAL OF NEURAL TRANSMISSION (2004)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
5-HT1A receptor knockout mouse as a genetic model of anxiety
M Toth
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Is there a role for 5-HT1A agonists in the treatment of depression?
P Blier et al.
BIOLOGICAL PSYCHIATRY (2003)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor.: III.: Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes
A Newman-Tancredi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
AJ Harding et al.
BRAIN (2002)
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease
AJ Hughes et al.
NEUROLOGY (2001)
Binding of antipsychotic drugs to human brain receptors - Focus on newer generation compounds
E Richelson et al.
LIFE SCIENCES (2000)
Organization of the basal ganglia:: the importance of axonal collateralization
A Parent et al.
TRENDS IN NEUROSCIENCES (2000)
Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study
D Aarsland et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2000)
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635 -: Effects of depression and antidepressant treatment
PA Sargent et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Share Paper
